Nhej vs Hdr in CRISPR: Which Repair Path Your Experiment Is Using

NHEJ versus HDR DNA-repair pathways in CRISPR experiments are the two routes a cell uses after a Cas nuclease cuts both DNA strands. They are not two CRISPR enzymes. Cas (commonly Cas9) creates the double-strand break; the cell then either joins the free ends through non-homologous end joining (NHEJ) or copies from a homologous sequence through homology-directed repair (HDR). Which path is available — and what you must put into the transfection — decides whether the experiment is a knockout or a templated knock-in.

Two Repair Paths, Not Two CRISPR Enzymes

The practical difference starts after the cut. Addgene's CRISPR 101 note on HDR states that eukaryotic double-strand breaks are repaired primarily by NHEJ or HDR: NHEJ ligates sticky or blunt ends and often introduces small insertions or deletions, while HDR uses homologous sequence as a template and is the more accurate of the two when that template matches the intended sequence. Ran and colleagues (2013) built the widely used Cas9 protocol around the same fork — editing via NHEJ or via HDR in mammalian cells — which is why a methods paper can describe both outcomes without changing the nuclease.

Jasin and Rothstein (2013) review the underlying homologous-recombination logic: repair that uses a homologous DNA sequence, not a second Cas protein. In a CRISPR experiment that homology can be a sister chromatid or, more often for knock-ins, a donor you supply. The enzyme on the bench is still Cas plus a guide. The variable that changes the genotype is which repair path the cell takes at that break.

NHEJ vs HDR at the Bench: A Comparison Table

A 2020 review of CRISPR pathway choice summarizes the bias that every mammalian experimenter runs into: NHEJ is active throughout the cell cycle except mitosis, HDR is restricted to S and G2, NHEJ is faster than HDR, and NHEJ can repress HDR. That review also restates the outcomes Addgene names — NHEJ tends to leave insertions or deletions at the cut; HDR can copy an exogenous template. Efficiency percentages in the wider literature are locus- and system-specific, so they are not repeated here as if they were constants.

What You Have to Supply for the Path You Want

If the experimental goal is loss of function, the matching setup is NHEJ: deliver the nuclease and a guide that cuts in a coding exon, then screen for indels. You are not omitting a reagent; you are using the path that does not need a template. If the goal is a precise amino-acid change, a tag, or another specified insertion, the experiment depends on HDR and the extra input is the donor. Addgene's HDR note treats donor class as a function of edit size — short single-stranded oligos for small changes, plasmid or other dsDNA for large cassettes — and warns that Cas will keep cutting if the guide or PAM still matches after a successful edit. Those design details vary by locus; they are constraints, not a single recipe.

Two consequences follow. First, "we transfected Cas9" does not tell a collaborator which path you needed. Second, an HDR plasmid sitting in the freezer does not convert a cycling, G1-heavy culture into an HDR-competent system. The cell-cycle window still applies.

Where Guide Design Fits After the Biology

Guide-design software answers a different question: where can this nuclease cut, and which similar genomic sites look risky. It does not switch NHEJ off or HDR on. A high on-target score is not evidence that a knock-in will land, and a clean off-target list is not a repair-path setting. After the pathway is chosen, scoring is still useful — the cut site has to exist, and off-target risk is independent of whether you later add a donor. ZettaCRISPR is one workspace example of that scoring job: the Zettalab product page documents CRISPR guide-RNA design with on- and off-target scoring. That capability nominates guides; it does not choose NHEJ or HDR and it does not guarantee an edit. The CRISPOR versus commercial CRISPR software comparison is the next page if the remaining decision is which scoring tool the lab will sit in.

When a Knockout-Only Setup Is Still the Right Call

A knockout that only needs a frameshift does not become more rigorous because a donor was added. NHEJ without a template is the matching design, not a shortcut. This page stops before the literature on NHEJ inhibitors, cell-cycle synchronization, and other HDR-boosting tactics — those are methods papers, not a definition of the two paths. It also makes no clinical or therapeutic claim. Pathway choice in a dish is not a safety argument for editing people.

Frequently Asked Questions

Are NHEJ and HDR two different CRISPR enzymes?

No. The nuclease makes the double-strand break. NHEJ and HDR are the cell's repair paths at that break. You change enzymes when you swap Cas9 for another nuclease; you change paths when you add or omit a homologous donor and accept the cell-cycle constraints that come with HDR.

Why is HDR usually harder than making a knockout in the same cells?

HDR requires a homologous donor and is largely limited to S and G2, while NHEJ is available through most of the cell cycle and is faster. Those constraints are why the same Cas cut yields indels more readily than a specified insertion. Published HDR frequencies vary by locus and system, so a single percentage is not a planning number.

Do I need a donor DNA template for an NHEJ knockout?

No. A typical NHEJ knockout uses Cas and a guide and relies on insertions or deletions at the cut. The donor is the extra input an HDR experiment must supply. If a "knockout" plasmid still carries homology arms, ask whether someone actually designed an HDR allele by habit.

Can CRISPR design software choose NHEJ or HDR for me?

No. Design tools rank candidate guides for a chosen genome. The cell still chooses the repair path, and a score does not guarantee a knockout or a knock-in. Use software after you know which path the genotype requires.